ANTICANCER FUSION PROTEIN

A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity, preferably 85% identity and ending with th...

Full description

Saved in:
Bibliographic Details
Main Authors PIECZYKOLAN, JERZY SZCZEPAN, ZEREK, BARTLOMIEJ MACIEJ, PIECZYKOLAN, ANNA MARIA, PAWLAK, SEBASTIAN, SZYMANIK, MICHAL, RÓZGA, PIOTR, JAWORSKI, ALBERT ROBERT, TESKA-KAMINSKA, MALGORZATA IZABELA
Format Patent
LanguageEnglish
Published 27.06.2014
Subjects
BEER
BIOCHEMISTRY
CHEMISTRY
COMPOSITIONS THEREOF
CULTURE MEDIA
ENZYMOLOGY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
MICROBIOLOGY
MICROORGANISMS OR ENZYMES
MUTATION OR GENETIC ENGINEERING
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS
SPIRITS
VINEGAR
WINE
Online AccessGet full text

Cover

More Information
Summary:A fusion protein comprising domain (a) which is a functional fragment of hTRAIL protein sequence, which fragment begins with an amino acid at a position not lower than hTRAIL95, or a homolog of said functional fragment having at least 70% sequence identity, preferably 85% identity and ending with the amino acid hTRAIL281; and domain (b) which is a sequence of an effector peptide inhibiting protein synthesis, wherein the sequence of domain (b) is attached at the C-terminus or N-terminus of domain (a). The fusion protein can be used for the treatment of cancer diseases.
Bibliography:Application Number: SG20141102312W